Drug Profile
Research programme: diabetes/obesity therapy - LadRx Corporation
Alternative Names: Obesity therapy research programme - LadRx Corporation; Rip140Latest Information Update: 29 Sep 2022
Price :
$50
*
At a glance
- Originator Imperial Innovations
- Developer LadRx Corporation
- Class Small interfering RNA
- Mechanism of Action Genetic transcription inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Obesity; Type 2 diabetes mellitus
Most Recent Events
- 23 Sep 2022 CytRx Corporation is now called LadRx Corporation
- 05 Dec 2008 Discontinued - Preclinical for Obesity in USA (unspecified route)
- 05 Dec 2008 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)